AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
15 Feb 2018 07:00 AM
RNS
Selumetinib in NF1 gets FDA orphan drug status
05 Feb 2018 02:00 PM
RNS
Director/PDMR Shareholding
02 Feb 2018 07:00 AM
RNS
AZN: Full-Year 2017 Results
01 Feb 2018 03:00 PM
RNS
Total Voting Rights
26 Jan 2018 06:20 PM
RNS
AZ Reports Phase III Results for PT010 in COPD
26 Jan 2018 07:00 AM
RNS
AZ Reports Phase III Results for PT010 in COPD
19 Jan 2018 07:00 AM
RNS
LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER
19 Jan 2018 07:00 AM
RNS
ASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPAN
12 Jan 2018 04:10 PM
RNS
FDA approves Lynparza for metastatic breast cancer
10 Jan 2018 03:10 PM
RNS
AstraZeneca's Fasenra approved in the EU
02 Jan 2018 03:00 PM
RNS
Total Voting Rights
28 Dec 2017 02:00 PM
RNS
Director/PDMR Shareholding
18 Dec 2017 07:00 AM
RNS
FDA accepts Tagrisso submission for 1st-line nsclc
15 Dec 2017 12:00 PM
RNS
Director/PDMR Shareholding
01 Dec 2017 03:00 PM
RNS
Block listing Interim Review
01 Dec 2017 03:00 PM
RNS
Total Voting Rights
28 Nov 2017 07:00 AM
RNS
EMA accepts Tagrisso submission for 1st-line nsclc
27 Nov 2017 07:00 AM
RNS
AZ submits Tagrisso in Japan for 1st-line nsclc
15 Nov 2017 07:00 AM
RNS
AZ Fasenra receives FDA approval for severe asthma
10 Nov 2017 11:35 AM
RNS
BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA
09 Nov 2017 07:00 AM
RNS
AZN: Year-To-Date and Q3 2017 Results Announcement
01 Nov 2017 03:00 PM
RNS
Total Voting Rights
01 Nov 2017 07:03 AM
RNS
ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL
01 Nov 2017 07:00 AM
RNS
AstraZeneca tralokinumab update in severe asthma
31 Oct 2017 05:05 PM
RNS
US FDA approves AstraZeneca's Calquence for MCL
23 Oct 2017 07:05 AM
RNS
AZ and MSD rapidly advance Lynparza in Japan
23 Oct 2017 07:00 AM
RNS
US FDA approves Bydureon BCise for type-2 diabetes
18 Oct 2017 07:00 AM
RNS
FDA Priority Review for Lynparza in breast cancer
17 Oct 2017 07:00 AM
RNS
FDA accepts sBLA file for Imfinzi; priority review
09 Oct 2017 07:00 AM
RNS
FDA grants Tagrisso BTD for 1st-line EGFR nsclc
02 Oct 2017 03:00 PM
RNS
Total Voting Rights
26 Sep 2017 12:00 PM
RNS
Director/PDMR Shareholding
14 Sep 2017 07:00 AM
RNS
Aspen acquires remaining rights to AZ anaesthetics
11 Sep 2017 07:00 AM
RNS
Tagrisso potential standard of care in lung cancer
11 Sep 2017 07:00 AM
RNS
IMFINZI superior PFS in Stage III lung cancer
07 Sep 2017 12:39 PM
RNS
Celgene and AZ update on Fusion trial programme
07 Sep 2017 07:00 AM
RNS
AZ Duaklir improves lung function in COPD patients
07 Sep 2017 07:00 AM
RNS
AZ tezepelumab cuts exacerbations in severe asthma
05 Sep 2017 07:00 AM
RNS
Directorate Change
01 Sep 2017 03:00 PM
RNS
Total Voting Rights
29 Aug 2017 07:00 AM
RNS
Faslodex gets US FDA OK for expanded use in breast
18 Aug 2017 07:00 AM
RNS
Lynparza gets broad FDA approval in ovarian cancer
16 Aug 2017 07:00 AM
RNS
Directorate Change
14 Aug 2017 04:30 PM
RNS
Holding(s) in Company
10 Aug 2017 01:30 PM
RNS
Publication of a Prospectus
02 Aug 2017 07:00 AM
RNS
AZ acalabrutinib submission accepted by US FDA
01 Aug 2017 03:00 PM
RNS
Total Voting Rights
01 Aug 2017 07:00 AM
RNS
BTD for AZ's acalabrutinib in mantle cell lymphoma
31 Jul 2017 07:00 AM
RNS
Imfinzi granted BTD by US FDA for Stage III nsclc
28 Jul 2017 11:00 AM
RNS
Director/PDMR Shareholding
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings